Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
Nasser H. Hanna
No relevant relationships to disclose
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Richard N. Sullivan
No relevant relationships to disclose
Osvaldo Rudy Aren
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Beatrice Tiangco
No relevant relationships to disclose
Zanete Zvirbule
No relevant relationships to disclose
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Ahmet Demirkazik
No relevant relationships to disclose
Birgit Gaschler-Markefski
Employment or Leadership Position - Boehringer Ingelheim
Isabelle Voccia
Employment or Leadership Position - Boehringer Ingelheim
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Joo-Hang Kim
Research Funding - Boehringer Ingelheim